Prostaview (FC303, [18F]florastamin)
ApprovedA PSMA-targeted PET diagnostic for prostate cancer, approved in April 2026 as Korea's 43rd new drug, with a positive predictive value of 86.96% in Phase 3.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Won approval for a new prostate cancer diagnostic and started the Korean Phase 3 trial of its therapy candidate FC705.
Roles often seen at this stageClinical & PV · Regulatory affairs · Manufacturing & MSAT
A radiopharmaceutical company with diagnostic agents for lung cancer (FLT), Parkinson's disease (PDview), Alzheimer's disease (Alzavue) and prostate cancer (Prostaview), and the prostate cancer therapy candidate FC705.
A PSMA-targeted PET diagnostic for prostate cancer, approved in April 2026 as Korea's 43rd new drug, with a positive predictive value of 86.96% in Phase 3.
A radiopharmaceutical candidate for metastatic castration-resistant prostate cancer in a 114-patient Phase 3 trial at eight Korean hospitals.
A PET radiopharmaceutical for diagnosing Alzheimer's disease.
Received Korean approval for the FC705 Phase 3 trial plan.
Dosed the first patient in the Korean FC705 Phase 3 trial at Seoul St. Mary's Hospital.
The prostate cancer diagnostic Prostaview Injection received new-drug approval from Korea's Ministry of Food and Drug Safety.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.